Zeneca Acquires US Rights to Kadian, an Oral Morphine Product

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 5
Volume 5
Issue 5

WILMINGTON, Del--Zeneca Inc. has reached an agreement with Faulding Services Inc. (Adelaide, South Australia) for exclusive US rights to purchase, distribute, and promote Faulding's sustained-release morphine sulfate product Kadian, an oral medication taken once or twice daily.

WILMINGTON, Del--Zeneca Inc. has reached an agreement with FauldingServices Inc. (Adelaide, South Australia) for exclusive US rightsto purchase, distribute, and promote Faulding's sustained-releasemorphine sulfate product Kadian, an oral medication taken onceor twice daily.

A new drug application (NDA) for use of Kadian in the treatmentof moderate to severe chronic pain is currently under FDA review.The product is approved and available in Australia and severalEuropean countries.

Articles in this issue
No Need to Delay Mammography After FNA, Study Shows
Pediatric Cancer Guidelines Are a National Effort
EPA Proposes Changes in Determining Cancer Risk of Chemicals, Pollutants
ATL's HDI Digital Ultrasound Is Approved for Breast Indication
Cell-Adhesion Molecules May Be Key to Controlling Metastases in Breast Cancer
NIH Study Suggests That 200 mg Is The Optimal Daily Dose of Vitamin C
Natural History of HIV Supports the Use Of Early Interventions
Aids Vaccine Trial Fails to Show Clinical Benefit
Rep. Porter Honored For Work on Budget
Forum Airs Issue of Who Should Pay for Patient Care in Cancer Clinical Trials
Blenoxane Cleared for New Use In Malignant Pleural Effusion
Implementation of Critical Path Reduces Prostatectomy Costs
Berlex Foundation Seeks Workshop Applicants
Networking Venture Benefits Both
Health of Biotech Industry a Concern to Oncologists

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content
92 Near-Infrared Fluorescence Imaging With Indocyanine Green vs Isosulfan Blue for Sentinel Lymph Node Mapping: Comparative Cost Analysis in Early-Stage Breast Cancer

92 Near-Infrared Fluorescence Imaging With Indocyanine Green vs Isosulfan Blue for Sentinel Lymph Node Mapping: Comparative Cost Analysis in Early-Stage Breast Cancer

Michelle Sosa;Deirdre McNicholas;Arbelina Bebla;Seth Emont;Zhun Cao;Manu Tyagi;Craig Lipkin;Sommer Gunia
April 19th 2025
Article
Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Multivariate analysis showed consolidative thoracic radiotherapy improved OS/PFS vs control patients with ES-SCLC, with respective HRs of 0.53 and 0.90.

Consolidative Thoracic Radiotherapy Improves Survival in ES-SCLC

Roman Fabbricatore
April 18th 2025
Article

Multivariate analysis showed consolidative thoracic radiotherapy improved OS/PFS vs control patients with ES-SCLC, with respective HRs of 0.53 and 0.90.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Patients with painful lesions who did not undergo treatment with opioids or reirradiation generally had better outcomes than those who did.

Classification System May Identify QOL Benefit with Palliative Radiotherapy

Roman Fabbricatore
April 18th 2025
Article

Patients with painful lesions who did not undergo treatment with opioids or reirradiation generally had better outcomes than those who did.

UK’s MHRA Approves Belantamab Mafodotin/Chemo in Myeloma Indications

UK’s MHRA Approves Belantamab Mafodotin/Chemo in Myeloma Indications

Tim Cortese
April 18th 2025
Article

Results from the DREAMM-7 and DREAMM-8 trials support the approval of belantamab mafodotin with chemotherapy in relapsed/refractory multiple myeloma.